Voyager Therapeutics (NASDAQ:VYGR) Shares Down 1.6%

Voyager Therapeutics, Inc. (NASDAQ:VYGR)’s stock price traded down 1.6% during trading on Friday . The company traded as low as $8.62 and last traded at $8.64. 72,492 shares changed hands during mid-day trading, a decline of 92% from the average session volume of 945,859 shares. The stock had previously closed at $8.78.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on VYGR. HC Wainwright assumed coverage on Voyager Therapeutics in a research report on Tuesday, March 19th. They set a “buy” rating and a $30.00 target price on the stock. Guggenheim began coverage on shares of Voyager Therapeutics in a research report on Tuesday, March 26th. They set a “buy” rating and a $22.00 price target for the company. Wells Fargo & Company raised shares of Voyager Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $9.00 to $14.00 in a research report on Tuesday, January 2nd. StockNews.com raised shares of Voyager Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, March 9th. Finally, Citigroup started coverage on Voyager Therapeutics in a research report on Thursday, March 7th. They set a “buy” rating and a $16.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, Voyager Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $19.33.

Voyager Therapeutics Stock Performance

The stock’s 50 day simple moving average is $8.76 and its 200-day simple moving average is $7.95. The firm has a market cap of $457.75 million, a price-to-earnings ratio of 2.73 and a beta of 0.96.

Voyager Therapeutics (NASDAQ:VYGR) last issued its earnings results on Wednesday, February 28th. The company reported $1.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.59) by $1.84. The company had revenue of $90.06 million during the quarter, compared to analyst estimates of $4.95 million. Voyager Therapeutics had a return on equity of 63.89% and a net margin of 52.93%. On average, analysts expect that Voyager Therapeutics, Inc. will post -1.64 EPS for the current fiscal year.

Hedge Funds Weigh In On Voyager Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Gladius Capital Management LP acquired a new stake in Voyager Therapeutics during the 3rd quarter valued at approximately $25,000. Ameritas Investment Partners Inc. purchased a new stake in Voyager Therapeutics in the second quarter valued at $30,000. AJOVista LLC acquired a new stake in Voyager Therapeutics during the 4th quarter worth about $39,000. UBS Group AG purchased a new position in shares of Voyager Therapeutics during the 1st quarter valued at about $39,000. Finally, China Universal Asset Management Co. Ltd. acquired a new position in shares of Voyager Therapeutics in the 4th quarter valued at about $43,000. Institutional investors and hedge funds own 48.03% of the company’s stock.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.